PriceTargets.com logo

Pacific Biosciences of California - PACB Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $12.75
  • Forecasted Upside: 2.16%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$12.48 As of 05/26/2023 09:47 PM ET
▲ +0.51 (4.26%)

This chart shows the closing price for PACB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pacific Biosciences of California Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PACB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PACB

Analyst Price Target is $12.75
▲ +2.16% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Pacific Biosciences of California in the last 3 months. The average price target is $12.75, with a high forecast of $15.00 and a low forecast of $8.00. The average price target represents a 2.16% upside from the last price of $12.48.

This chart shows the closing price for PACB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 investment analysts is to hold stock in Pacific Biosciences of California. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2023BarclaysInitiated CoverageEqual Weight$14.00Low
5/8/2023Piper SandlerBoost Target$10.00 ➝ $13.00Low
5/3/2023SpectralCastReiterated RatingMaintainsLow
5/3/2023Cantor FitzgeraldBoost Target$12.00 ➝ $13.00Low
3/31/2023TD CowenUpgradeMarket Perform ➝ Outperform$13.00 ➝ $15.00Low
2/22/2023Piper SandlerLower Target$11.00 ➝ $10.00Low
2/2/2023UBS GroupInitiated CoverageNeutral$13.00Low
1/20/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral$12.00Low
1/4/2023ScotiabankInitiated CoverageSector Outperform$12.00Low
11/16/2022Canaccord Genuity GroupBoost Target$12.00 ➝ $14.00Low
11/16/2022Piper SandlerBoost Target$6.00 ➝ $11.00Low
8/21/2022Piper SandlerLower Target$7.50 ➝ $6.00Low
8/17/2022Piper SandlerBoost TargetNeutral$6.00 ➝ $7.50Low
8/9/2022CowenLower Target$8.00Low
8/5/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$17.00 ➝ $14.00Low
7/19/2022CowenSet Target$9.00Low
5/15/2022Piper SandlerLower TargetNA$13.00 ➝ $6.00High
5/5/2022Cantor FitzgeraldLower Target$23.00 ➝ $19.00High
3/1/2022Piper SandlerLower Target$20.00 ➝ $13.00High
2/16/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$45.00 ➝ $40.00High
2/16/2022Canaccord Genuity GroupLower TargetBuy$45.00 ➝ $40.00High
1/25/2022Cantor FitzgeraldReiterated RatingOverweightHigh
8/4/2021Morgan StanleyLower TargetEqual Weight$45.00 ➝ $41.00High
7/9/2021Cantor FitzgeraldReiterated RatingOverweightHigh
2/12/2021Morgan StanleyBoost TargetEqual Weight$12.00 ➝ $45.00Low
2/11/2021Cantor FitzgeraldBoost TargetIn-Line ➝ Overweight$45.00 ➝ $62.00Low
2/11/2021Piper SandlerUpgradeNeutral ➝ Overweight$20.00 ➝ $52.00Low
1/15/2021Piper SandlerBoost TargetNeutral$12.00 ➝ $20.00Medium
1/12/2021Cantor FitzgeraldBoost TargetReduce ➝ Overweight$25.00 ➝ $45.00Medium
12/8/2020Cantor FitzgeraldBoost TargetOverweight$16.00 ➝ $25.00Low
11/4/2020Morgan StanleyBoost TargetEqual Weight$7.00 ➝ $12.00High
11/3/2020Piper SandlerDowngradeOverweight ➝ Neutral$12.00High
10/13/2020Cantor FitzgeraldBoost TargetOverweight$11.00 ➝ $17.00High
10/2/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$15.00Low
10/1/2020Piper SandlerBoost TargetOverweight$6.00 ➝ $12.00High
9/9/2020Morgan StanleyInitiated CoverageEqual Weight$7.00Low
6/10/2020Cantor FitzgeraldReiterated RatingBuy$5.00High
6/1/2020Cantor FitzgeraldInitiated CoverageBuy$5.00High
5/7/2020Piper SandlerLower TargetOverweight$7.00 ➝ $6.00Medium
4/17/2020Cantor FitzgeraldReiterated RatingOverweightMedium
3/9/2020Cantor FitzgeraldReiterated RatingOverweight$5.00Medium
12/18/2019Piper Jaffray CompaniesReiterated RatingBuy$7.00Low
10/15/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$8.00High
6/20/2019Cantor FitzgeraldSet TargetHold$8.00Low
6/13/2019Cantor FitzgeraldReiterated RatingHoldLow
5/3/2019Cantor FitzgeraldReiterated RatingHold$8.00Low
4/2/2019StephensDowngradeOverweight ➝ Equal Weight$4.50 ➝ $8.00Low
1/4/2019CowenDowngradeOutperform ➝ Market PerformLow
11/12/2018Cantor FitzgeraldDowngradeOverweight ➝ Neutral$8.00Low
11/1/2018Cantor FitzgeraldSet TargetBuy$8.00Medium
10/21/2018Cantor FitzgeraldReiterated RatingBuy$8.00Low
10/19/2018CowenInitiated CoverageOutperform ➝ Outperform$6.50High
10/11/2018Cantor FitzgeraldSet TargetBuy$8.00Medium
8/8/2018Cantor FitzgeraldInitiated CoverageOverweight$5.00High
8/3/2018Piper Jaffray CompaniesReiterated RatingHold$3.80High
(Data available from 5/29/2018 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/31/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 6 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
2/28/2023
  • 6 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023
  • 5 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/29/2023
  • 7 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/29/2023

Current Sentiment

  • 7 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Pacific Biosciences of California logo
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
Read More

Today's Range

Now: $12.48
Low: $12.03
High: $12.89

50 Day Range

MA: $11.13
Low: $8.36
High: $13.06

52 Week Range

Now: $12.48
Low: $3.85
High: $14.20

Volume

3,718,900 shs

Average Volume

4,017,516 shs

Market Capitalization

$3.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Pacific Biosciences of California?

The following sell-side analysts have issued stock ratings on Pacific Biosciences of California in the last year: Barclays PLC, Canaccord Genuity Group Inc., Cantor Fitzgerald, Cowen Inc., Piper Sandler, Scotiabank, SpectralCast, Inc., TD Cowen, and UBS Group AG.
View the latest analyst ratings for PACB.

What is the current price target for Pacific Biosciences of California?

8 Wall Street analysts have set twelve-month price targets for Pacific Biosciences of California in the last year. Their average twelve-month price target is $12.75, suggesting a possible upside of 2.2%. TD Cowen has the highest price target set, predicting PACB will reach $15.00 in the next twelve months. Cowen Inc. has the lowest price target set, forecasting a price of $8.00 for Pacific Biosciences of California in the next year.
View the latest price targets for PACB.

What is the current consensus analyst rating for Pacific Biosciences of California?

Pacific Biosciences of California currently has 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PACB, but not buy more shares or sell existing shares.
View the latest ratings for PACB.

What other companies compete with Pacific Biosciences of California?

Other companies that are similar to Pacific Biosciences of California include Bio-Rad Laboratories, Olink Holding AB (publ), Cytek Biosciences, Quanterix and 10x Genomics. Learn More about companies similar to Pacific Biosciences of California.

How do I contact Pacific Biosciences of California's investor relations team?

Pacific Biosciences of California's physical mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company's listed phone number is (650) 521-8000 and its investor relations email address is [email protected]. The official website for Pacific Biosciences of California is www.pacb.com. Learn More about contacing Pacific Biosciences of California investor relations.